TRIMPEX 200
LOE ApproachingNDAORALTABLET
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIMPEX 200 is an oral tablet NDA approved by Roche in 1980 with unknown mechanism of action and indication profile. The drug's specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal competitive pressure reported (30), brand team size is likely small and focused on managed decline or niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TRIMPEX 200 currently has zero linked job openings, reflecting its late-stage lifecycle and mature market position. Career opportunities are limited to commercial optimization, managed care negotiation, and defensive positioning against generics rather than growth or innovation initiatives.
Brand ManagerMarketing Manager
Worked on TRIMPEX 200 at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.